Novel strategies for the treatment and diagnosis of graft-versus-host-disease

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 1, 2007, Pages 91-97

  Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

graft versus host disease; hematopoietic stem cell transplant; TNF

Indexed keywords

DENILEUKIN DIFTITOX; ETANERCEPT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LIVER DISEASE; LUNG DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SKIN DISEASE; STEROID THERAPY; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTICENTER STUDIES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847332477     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.11.004     Document Type: Review

References (21)

1. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
2. Murphy G.F., and Korngold R. Significance of selectively targeted apoptotic rete cells in graft-versus-host disease. Biology of Blood and Marrow Transplantation 10 (2004) 357-365
3. Yanik G., and Cooke K.R. The lung as a target organ of graft-versus-host disease. Seminars in Hematology 43 (2006) 42-52
4. Perrotta P.L., and Snyder E.L. Non-infectious complications of transfusion therapy. Blood Reviews 15 (2001) 69-83
5. Abo-Zena R.A., and Horwitz M.E. Immunomodulation in stem-cell transplantation. Current Opinion in Pharmacology 2 (2002) 452-457
6. Weisdorf D.J. Phase II randomized study of etanercept versus mycophenolate mofetil versus denileukin diftitox versus pentostatin in combination with prednisone or methylprednisolone in patients with acute graft-versus-host disease who have undergone a prior allogeneic hematopoietic stem cell transplant (2006). http://www.clinicaltrials.gov/ct/show/NCT00253656?order=1
7. Goker H., Haznedaroglu I.C., and Chao N.J. Acute graft-vs-host disease: pathobiology and management. Experimental Hematology 29 (2001) 259-277
8. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Seminars in Hematology 43 (2006) 3-10
9. Simpson E. Minor transplantation antigens: animal models for human host-versus-graft, graft-versus-host, and graft-versus-leukemia reactions. Transplantation 65 (1998) 611-616
10. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine 8 (2002) 575-581
11. Korngold R., Marini J.C., de Baca M.E., et al. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biology of Blood and Marrow Transplantation 9 (2003) 292-303
12. Ferrara J.L., Levy R., and Chao N.J. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biology of Blood and Marrow Transplantation 5 (1999) 347-356
13. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
14. Cooke K.R., Hill G.R., Crawford J.M., et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. The Journal of Clinical Investigation 102 (1998) 1882-1891
15. Yanik G.A., Uberti J.P., Ferrara J.L.M., et al. Etanercept for sub-acute lung injury following allogeneic stem cell transplantation. Blood 102 (2003) 471a (abstract)
16. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biology of Blood and Marrow Transplantation 11 (2005) 680-687
17. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
18. Chiang K.Y., Abhyankar S., Bridges K., et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 73 (2002) 665-667
19. Hill G.R., Crawford J.M., Cooke K.R., et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
20. Baker K.S., Allen R.D., Roths J.B., et al. Kinetic and organ-specific patterns of cytokine expression in acute graft-versus-host disease. Bone Marrow Transplantation 15 (1995) 595-603
21. Levine J.E., Yanik G.A., Cooke K.R., et al. Elevated TNF receptor levels early after myeloablative BMT predict for GVHD and death. Biology of Blood and Marrow Transplantation (2006) 12 (abstract 138)